Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE Jr, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1802-1815.e5. doi: 10.1016/j.celrep.2018.07.035.

2.

Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Iampietro M, Santos RI, Lubaki NM, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S327-S334. doi: 10.1093/infdis/jiy406.

PMID:
30085081
3.

Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.

Younan P, Iampietro M, Nishida A, Ramanathan P, Santos RI, Dutta M, Lubaki NM, Koup RA, Katze MG, Bukreyev A.

MBio. 2017 Sep 26;8(5). pii: e00845-17. doi: 10.1128/mBio.00845-17.

4.

Erratum to: Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W.

Protein Cell. 2018 Oct;9(10):902. doi: 10.1007/s13238-017-0427-1. No abstract available.

5.

Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.

Iampietro M, Younan P, Nishida A, Dutta M, Lubaki NM, Santos RI, Koup RA, Katze MG, Bukreyev A.

PLoS Pathog. 2017 May 22;13(5):e1006397. doi: 10.1371/journal.ppat.1006397. eCollection 2017 May.

6.

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W.

Protein Cell. 2017 Dec;8(12):861-877. doi: 10.1007/s13238-017-0415-5. Epub 2017 May 9. Review. Erratum in: Protein Cell. 2017 Jun 23;:.

7.

The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.

Lubaki NM, Younan P, Santos RI, Meyer M, Iampietro M, Koup RA, Bukreyev A.

PLoS Pathog. 2016 Dec 8;12(12):e1006031. doi: 10.1371/journal.ppat.1006031. eCollection 2016 Dec.

8.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

9.

Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.

Ilinykh PA, Lubaki NM, Widen SG, Renn LA, Theisen TC, Rabin RL, Wood TG, Bukreyev A.

J Virol. 2015 Aug;89(15):7567-83. doi: 10.1128/JVI.00924-15. Epub 2015 May 13.

10.

The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA, Bukreyev A.

J Virol. 2013 Jul;87(13):7471-85. doi: 10.1128/JVI.03316-12. Epub 2013 Apr 24. Erratum in: J Virol. 2013 Nov;87(22):12506.

11.

Genetic diversification and recombination of HIV type 1 group M in Kinshasa, Democratic Republic of Congo.

Yang C, Li M, Mokili JL, Winter J, Lubaki NM, Mwandagalirwa KM, Kasali MJ, Losoma AJ, Quinn TC, Bollinger RC, Lal RB.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):661-6.

PMID:
16060838
12.

HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.

Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, Johnson M, Gottle R, Devers J, Lederman HM, Bollinger RC.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30.

PMID:
10534143
13.

Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression.

Lubaki NM, Ray SC, Dhruva B, Quinn TC, Siliciano RF, Bollinger RC.

J Infect Dis. 1997 Jun;175(6):1360-7.

PMID:
9180175

Supplemental Content

Loading ...
Support Center